Research and development (R&D) at Vernalis is focused on the goal of developing novel medicines that are commercially attractive.
Product Pipeline
Frovatriptan is a selective 5-HT1B/D receptor agonist approved as an acute oral treatment for migraine headache and its associated symptoms.
V3381 is a novel drug candidate that is in phase II development for the treatment of neuropathic pain.
V2006 is an adenosine A2A receptor antagonist in phase II development as a potential novel treatment for Parkinson's disease.
V85546 is a selective MMP 12 (macrophage elastase) inhibitor which has been developed by Serono under a collaboration initiated in 2000.
NVP-AUY922
NVP-AUY922 is an iv formulation and a novel Hsp90 inhibitor for a range of cancers.
Hsp90 is a novel drug target, inhibition of which is believed to have significant potential in the treatment of a broad range of cancers.
Fatty Acid Amide Hydrolase (FAAH) has been the target for a
late-stage research programme for the management of pain and has
resulted in a lead molecule, V158866, advancing into pre-clinical
development in March 2009.
V158411 has been selected from out Checpoint Kinase 1 (Chk1) research programme in oncology. Chk1 inhibitors are used in conjunction with chemotherapy drugs and can be potentially be used to treat a broad range of tumour types including breat, prostate, colorectal and melanoma. They may also be used in haematological cancers such as lukaemia.
V1512 is an innovative, patented effervescent formulation combining levodopa (L-dopa) methyl-ester, a more soluble form of levodopa, and carbidopa.
V10153 is a novel recombinant thrombolytic protein which is being developed for the treatment of ischaemic stroke.
RPL554 is a novel long acting inhibitor of both phosphodiesterase 3 and phosphodesterase 4, two enzymes known to be of importance in the development and progression of immunological respiratory diseases, particularly rhinitis (hay fever) and asthma.
CHR-2797 (tosedostat) is a once daily, orally active aminopeptidase inhibitor which has been shown to halt cell growth or cause apoptosis (cell death) in a large number of cancer cell lines.
Product Pipeline
The discovery of novel medicines to treat human disease is the cornerstone of our business. To find out more details of the conditions we are seeking to treat - view our product pipeline.